Literature DB >> 26578740

Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients.

P Krawczyk1, K Reszka2, R Ramlau3, T Powrózek4, J Pankowski5, K Wojas-Krawczyk4, E Kalinka-Warzocha6, A Szczęsna6, M Nicoś4, B Jarosz7, K Szyszka-Barth3, M Bryl8, K Adamowicz9, J Szumiło10, J Milanowski4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26578740     DOI： 10.1093/annonc/mdv553

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.

Authors:  Pawel Krawczyk; Dariusz M Kowalski; Rodryg Ramlau; Ewa Kalinka-Warzocha; Kinga Winiarczyk; Katarzyna Stencel; Tomasz Powrózek; Katarzyna Reszka; Kamila Wojas-Krawczyk; Maciej Bryl; Magdalena Wójcik-Superczyńska; Maciej Głogowski; Aleksander Barinow-Wojewódzki; Janusz Milanowski; Maciej Krzakowski
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

2.  B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.

Authors:  Youwei Lu; Fengying Wu; Qiuyi Cao; Yu Sun; Moli Huang; Jing Xiao; Bin Zhou; Liang Zhang
Journal:  Oncogene       Date:  2021-11-27       Impact factor: 9.867

3.  Gene profiling of metastatic small intestinal squamous cell carcinoma after lung squamous cell carcinoma surgery: a case report.

Authors:  Fangchao Zhu; Jiejun Lin; Hongli Liao; Yunfei Wang; Jie Pan
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 0.496

Review 4.  Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review.

Authors:  Anna Rekowska; Piotr Rola; Magdalena Wójcik-Superczyńska; Izabela Chmielewska; Paweł Krawczyk; Janusz Milanowski
Journal:  Curr Oncol       Date:  2022-05-13       Impact factor: 3.109

5.  Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients.

Authors:  Anna Grenda; Bożena Jarosz; Paweł Krawczyk; Tomasz Kucharczyk; Kamila Wojas-Krawczyk; Katarzyna Reszka; Kinga Krukowska; Marcin Nicoś; Juliusz Pankowski; Maciej Bryl; Rodryg Ramlau; Barbara Kuźnar-Kamińska; Tomasz Grodzki; Aleksandra Szczęsna; Krystyna Siemiątkowska; Justyna Szumiło; Halina Batura-Gabryel; Michał Palonka; Janusz Milanowski
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 6.  Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.

Authors:  Julian Pinsolle; Anne McLeer-Florin; Matteo Giaj Levra; Florence de Fraipont; Camille Emprou; Elisa Gobbini; Anne-Claire Toffart
Journal:  Front Med (Lausanne)       Date:  2019-10-29

7.  Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.

Authors:  Jan Nyrop Jakobsen; Eric Santoni-Rugiu; Morten Grauslund; Linea Melchior; Jens Benn Sørensen
Journal:  Oncotarget       Date:  2018-05-25

8.  Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.

Authors:  Jinguang Wang; Xingya Li; Xingyang Xue; Qiuxiang Ou; Xue Wu; Ying Liang; Xiaonan Wang; Ming You; Yang W Shao; Zhihong Zhang; Shucai Zhang
Journal:  Int J Cancer       Date:  2018-12-16       Impact factor: 7.396
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.